{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T14:51:35Z","timestamp":1781362295051,"version":"3.54.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jfma.2026.01.035","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T04:33:35Z","timestamp":1769488415000},"page":"S13-S16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S1","title":["Alzheimer's disease diagnosis: An update and review of biomarkers, positron emission tomography, and emerging therapies"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8391-3088","authenticated-orcid":false,"given":"Pei-Hao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6422-8870","authenticated-orcid":false,"given":"Jung-Lung","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jfma.2026.01.035_bib1","first-page":"1","article-title":"Global burden of Alzheimer's disease and other dementias during 1990-2021: a global burden of disease and risk factors study 2021-based study","volume":"54","author":"Wang","year":"2025","journal-title":"Neuroepidemiology"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.035_bib2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3233\/JAD-240163","article-title":"Societal costs of dementia: 204 countries, 2000-2019","volume":"101","author":"Lastuka","year":"2024","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.035_bib3","article-title":"Focusing on earlier diagnosis of Alzheimer's disease","volume":"19","author":"Frederiksen","year":"2024","journal-title":"Future Neurol"},{"issue":"5","key":"10.1016\/j.jfma.2026.01.035_bib4","first-page":"1","article-title":"Alzheimer's disease facts and figures","volume":"20","year":"2024","journal-title":"Alzheimer's Dement"},{"issue":"7","key":"10.1016\/j.jfma.2026.01.035_bib5","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.jfma.2026.01.035_bib6","series-title":"The ICD-10 classification of mental and behavioural disorders","year":"2009"},{"key":"10.1016\/j.jfma.2026.01.035_bib7","series-title":"Diagnostic and statistical manual of mental disorders","year":"2013"},{"issue":"3","key":"10.1016\/j.jfma.2026.01.035_bib8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the NIA-AA workgroups","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer's Dement"},{"issue":"6","key":"10.1016\/j.jfma.2026.01.035_bib9","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.jfma.2026.01.035_bib10","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer's Dement"},{"issue":"8","key":"10.1016\/j.jfma.2026.01.035_bib11","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's association workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimer's Dement"},{"issue":"Supplement 1","key":"10.1016\/j.jfma.2026.01.035_bib12","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.2967\/jnumed.121.263195","article-title":"The role of amyloid PET in imaging neurodegenerative disorders: a review","volume":"63","author":"Chapleau","year":"2022","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.035_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2850","article-title":"Amyloid-\u03b2 PET in Alzheimer's disease: a systematic review and Bayesian meta-analysis","volume":"13","author":"Ruan","year":"2023","journal-title":"Brain and Behavior"},{"issue":"12","key":"10.1016\/j.jfma.2026.01.035_bib14","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.1002\/alz.14336","article-title":"Centiloid recommendations for clinical context-of-use from the AMYPAD consortium","volume":"20","author":"Collij","year":"2024","journal-title":"Alzheimer's Dement"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.035_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad305","article-title":"A review of the flortaucipir literature for PET imaging of tau neurofibrillary tangles","volume":"6","author":"Burnham","year":"2023","journal-title":"Brain Communications"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.035_bib16","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/s41398-021-01602-5","article-title":"Staging tau pathology with tau PET in Alzheimer's disease: a longitudinal study","volume":"11","author":"Chen","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"8","key":"10.1016\/j.jfma.2026.01.035_bib17","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/jamaneurol.2024.1612","article-title":"Tau positron emission tomography for predicting dementia in individuals with MCI","volume":"81","author":"Groot","year":"2024","journal-title":"JAMA Neurol"},{"issue":"14","key":"10.1016\/j.jfma.2026.01.035_bib18","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1212\/WNL.0000000000001991","article-title":"Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer's disease","volume":"85","author":"Palmqvist","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jfma.2026.01.035_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2023.120805","article-title":"Plasma p-tau181 is a promising non-invasive biomarker of AD pathology in SCD and MCI","volume":"453","author":"Giacomucci","year":"2023","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.035_bib20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3233\/ADR-230029","article-title":"Plasma biomarkers of Alzheimer's disease: a review","volume":"7","author":"Pais","year":"2023","journal-title":"J Alzheimers Dis Rep"},{"issue":"2","key":"10.1016\/j.jfma.2026.01.035_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14458","article-title":"Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer's disease pathology among cognitively impaired and unimpaired: a systematic review and meta-analysis","volume":"21","author":"Khalafi","year":"2025","journal-title":"Alzheimer's Dement"},{"issue":"11","key":"10.1016\/j.jfma.2026.01.035_bib22","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s43587-024-00731-y","article-title":"Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability","volume":"4","author":"Therriault","year":"2024","journal-title":"Nat Aging"},{"issue":"3","key":"10.1016\/j.jfma.2026.01.035_bib23","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5582\/ddt.2025.01055","article-title":"The pTau217\/A\u03b21-42 plasma ratio: the first FDA-cleared blood biomarker test for diagnosis of Alzheimer's disease","volume":"19","author":"Hu","year":"2025","journal-title":"Drug Discov Ther"},{"issue":"12","key":"10.1016\/j.jfma.2026.01.035_bib24","first-page":"3761","article-title":"The role of plasma NfL and GFAP in SCD and MCI","volume":"44","author":"Mazzeo","year":"2023","journal-title":"Neurol Sci"},{"issue":"22","key":"10.1016\/j.jfma.2026.01.035_bib25","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1016\/j.cell.2023.09.023","article-title":"Accelerating Alzheimer's therapeutic development: the past and future of clinical trials","volume":"186","author":"Boxer","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.035_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jfma.2026.01.035_bib27","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic alzheimer disease","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.jfma.2026.01.035_bib28","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"19","author":"Congdon","year":"2023","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"10.1016\/j.jfma.2026.01.035_bib29","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/d41573-024-00180-7","article-title":"Anti-tau antibody stumbles in phase II Alzheimer trial","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.jfma.2026.01.035_bib30","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jalz.2016.01.009","article-title":"Ethical challenges in preclinical Alzheimer's disease studies","volume":"12","author":"Molinuevo","year":"2016","journal-title":"Alzheimer's Dement"},{"issue":"4","key":"10.1016\/j.jfma.2026.01.035_bib31","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3233\/JAD-180638","article-title":"Ethical arguments concerning AD biomarkers use","volume":"66","author":"Smedinga","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.035_bib32","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12910-024-01141-w","article-title":"Ethical issues in genomics research in AD\/ADRD","volume":"25","author":"Yakubu","year":"2024","journal-title":"BMC Med Ethics"},{"issue":"3","key":"10.1016\/j.jfma.2026.01.035_bib33","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3390\/diagnostics11030440","article-title":"Ethical implications of AD prediction in asymptomatic individuals through AI","volume":"11","author":"Ursin","year":"2021","journal-title":"Diagnostics"},{"issue":"12","key":"10.1016\/j.jfma.2026.01.035_bib34","doi-asserted-by":"crossref","first-page":"5860","DOI":"10.1002\/alz.13390","article-title":"Artificial intelligence for biomarker discovery in AD and dementia","volume":"19","author":"Winchester","year":"2023","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.jfma.2026.01.035_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102497","article-title":"AI-driven innovations in Alzheimer's disease","volume":"101","author":"Kale","year":"2024","journal-title":"Ageing Res Rev"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.035_bib36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s13195-023-01304-8","article-title":"Systematic review: fluid biomarkers and ML methods to improve AD diagnosis","volume":"15","author":"Blanco","year":"2023","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.jfma.2026.01.035_bib37","first-page":"1","article-title":"Neuroinflammatory fluid biomarkers in AD","author":"Heneka","year":"2025","journal-title":"Mol Psychiatry"},{"issue":"4","key":"10.1016\/j.jfma.2026.01.035_bib38","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3233\/JAD-220515","article-title":"Synaptic proteins as fluid biomarkers in AD: a systematic review","volume":"90","author":"Roveta","year":"2022","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"10.1016\/j.jfma.2026.01.035_bib39","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3390\/biomedicines11020335","article-title":"The future of precision medicine in the cure of AD","volume":"11","author":"Arafah","year":"2023","journal-title":"Biomedicines"},{"issue":"16","key":"10.1016\/j.jfma.2026.01.035_bib40","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.3390\/jcm13164661","article-title":"Biomarker-based precision therapy for AD","volume":"13","author":"Bougea","year":"2024","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.jfma.2026.01.035_bib41","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1002\/alz.14184","article-title":"Recommendations for clinical implementation of blood-based biomarkers for AD","volume":"20","author":"Mielke","year":"2024","journal-title":"Alzheimer's Dement"},{"issue":"1","key":"10.1016\/j.jfma.2026.01.035_bib42","article-title":"Opportunities to encourage adoption of a biomarker-enabled care pathway for Alzheimer's in primary care","volume":"17","author":"Borson","year":"2025","journal-title":"Alzheimer's Dement"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664626000537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664626000537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T06:34:24Z","timestamp":1781159664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664626000537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":42,"alternative-id":["S0929664626000537"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2026.01.035","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alzheimer's disease diagnosis: An update and review of biomarkers, positron emission tomography, and emerging therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2026.01.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2026, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}